| Literature DB >> 33908778 |
Alessio Vidal1, Rudy Calligaro1, Gilles Gasser2, Roger Alberto3, Gabriele Balducci1, Enzo Alessio1.
Abstract
We describe a synthetic strategy for the preparation of bis-heterolepticEntities:
Year: 2021 PMID: 33908778 PMCID: PMC8154425 DOI: 10.1021/acs.inorgchem.1c00240
Source DB: PubMed Journal: Inorg Chem ISSN: 0020-1669 Impact factor: 5.165
Figure 1Two representative examples of bis-heteroleptic [Ru(L1)2(L2)]2+ compounds that are relevant in medicinal inorganic chemistry: [Ru(dppz)2(cppH)]2+ (left, cppH = 2-(2′-pyridyl)pyrimidine-4-carboxylic acid) and TLD1433 (right).
Figure 2Schematic representation of a cis-locked Ru(II)-DMSO precursor with a chelating oxygenated anion (O–O) developed in this work. X = DMSO or Cl. The charge (n = −1/0/+1) depends on the nature and charge of X and O–O. When present, Y = K+ or PF6–.
Scheme 1Schematic Representation of the Two-Step Preparation of Bis-Heteroleptic Products [Ru(L1)2(L2)]2+ (Exemplified for L1 = bpy) from a cis-Locked Ru(II)-DMSO Precursor
The charge of the starting compound (n) and of the intermediate (m) depends on the nature and charge of X and O–O. Counterion omitted.
Figure 3The six cis-locked Ru(II)-DMSO precursors [K]fac-[RuCl(DMSO–S)3(η2-mal)] (2), fac-[Ru(DMSO–O)(DMSO–S)3(η2-mal)] (3), [K] fac-[RuCl(DMSO–S)3(η2-ox)] (4), fac-[Ru(DMSO–O)(DMSO–S)3(η2-ox)] (5), fac-[RuCl(DMSO–S)3(η2-acac)] (6), and fac-[Ru(DMSO–O)(DMSO–S)3(η2-acac)][PF6] (7).
Scheme 2General Procedures for the Preparations of Complexes 3, 5, and 7 (X = CF3SO3, NO3, PF6) Exemplified in the Case of 5 (O–O = oxalate)
The blue part shows the preparation of the chloride-free precursor fac-[Ru(DMSO–O)3(DMSO–S)3][X]2.
Figure 4ORTEP representation (50% probability ellipsoids) of complex fac-[RuCl(DMSO–S)3(η2-acac)] (6, left) and of the cation of fac-[Ru(DMSO–O)(DMSO–S)3(η2-acac)][PF6] (7, right).
Scheme 3General Reactivity of the cis-Locked Dicarboxylate Precursors 2–5 towards bpy (Case of Malonate Is Exemplified)
Scheme 4General Reactivity of the cis-Locked acac Precursors 6 and 7 towards bpy
Figure 51H NMR spectrum (CDCl3) of [Ru(bpy)2(η2-mal)] (9). See the inset for labeling scheme.
Figure 6Complexes [Ru(phen)2(η2-mal)] (10), [Ru(dpphen)2(η2-mal)] (11), [Ru(phen)2(η2-ox)] (12), [Ru(dpphen)2(η2-ox)] (13), [Ru(phen)2(η2-acac)]Cl (14), and [Ru(dpphen)2(η2-acac)]Cl (15).
Figure 7ORTEP representation (50% probability ellipsoids) of complexes [Ru(phen)2(η2-mal)]·5H2O (10·5H2O, left) and [Ru(phen)2(η2-ox)]·H2O (12·H2O, right) in their crystal structures. Disordered cocrystallized water molecules have been omitted for clarity.
Figure 8ORTEP representation (50% probability ellipsoids) of the two independent molecules of compound [Ru(dpphen)2(η2-mal)]·3.75H2O (11·3.75H2O) in the crystal structure. Cocrystallized water molecules and H atoms have been omitted for clarity.
Figure 9UV–vis spectrum in chloroform of [Ru(dpphen)2(η2-mal)] (11).
Absorption Maxima and Extinction Coefficients in the UV–Vis Spectra (CHCl3) of Complexes 10–15
| compound | λmax (nm) | ε (L mol–1 cm–1) |
|---|---|---|
| [Ru(phen)2(η2-mal)] ( | 544 | 3.4 × 103 |
| [Ru(dpphen)2(η2-mal)] ( | 561 | 1.9 × 104 |
| [Ru(phen)2(η2-ox)] ( | 544 | 2.4 × 103 |
| [Ru(dpphen)2(η2-ox)]
( | 560 | 2.0 × 104 |
| [Ru(phen)2(η2-acac)]Cl ( | 509 | 1.1 × 104 |
| [Ru(dpphen)2(η2-acac)]Cl ( | 524 | 1.8 × 104 |
Scheme 5Acid-Assisted Facile and Selective Replacement of Malonate by bpy (TFA = trifluoracetic acid)
Scheme 6Hypothesis of the Two Parallel Routes Leading to the Mixture of [Ru(L1)2(O–O)] (Branch b) and [Ru(L1)3]2+ (Branch a) Exemplified for X = Cl–, L1 = bpy and O–O = mal